# Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile

> **NCT03321656** · PHASE2,PHASE3 · RECRUITING · sponsor: **Roberto Gedaly** · enrollment: 78 (estimated)

## Conditions studied

- End Stage Renal Disease

## Interventions

- **DRUG:** Tacrolimus
- **DRUG:** Envarsus XR

## Key facts

- **NCT ID:** NCT03321656
- **Lead sponsor:** Roberto Gedaly
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-03-28
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03321656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03321656, "Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03321656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*